Histone deacetylase inhibitors (HDACi) enhance oncolytic herpes simplex virus in malignant meningioma.

The goal of the study was to determine whether low dose HDACi sensitizes human malignant meningioma cells to the cytotoxic capacity of oncolytic herpes simplex virus G47delta. RNA sequencing was used to examine transcriptomic changes mediated by HDACi preexposure before oncolytic virus infection. Overall design: RNAseq data for CH-157 cells (CH) and IOMM-Lee cells (IOMM). Cells were untreated control (C; 1 and 2), or treated with G47delta (G; 3 and 4), Panobinostat (P, 5 and 6), or TrichostatinA (T, 7 and 8), Panobinostat and G47delta (P_G, 9 and 10), and TrichostatinA and G47delta (T_G, 11 and 12) before RNA extraction. Samples were labeled as CH1, CH2, CH3, CH4, CH5, CH6, CH7, CH8, CH9, CH10, CH11 CH12.